Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Study Phase : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Zydus Receives Tentative Approval from The USFDA For Levomilnacipran Extended-Release Capsules
Details : Fetzima® generic version (levomilnacipran) is an oral extended release capsule which selectively inhibits serotonin and norepinephrine reuptake (SNRI) and it has shown positive results for the treatment of major depressive disorder (MDD) in adults.
Product Name : Levomilnacipran-Generic
Product Type : Miscellaneous
Upfront Cash : Inapplicable
January 16, 2023
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Approved FDF
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Levomilnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 26, 2018
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levomilnacipran
Therapeutic Area : Undisclosed
Study Phase : Phase IV
Sponsor : Allergan
Deal Size : Inapplicable
Deal Type : Inapplicable
Levomilnacipran in Healthy Males
Details : Levomilnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of undefined medical condition.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
August 15, 2017
Lead Product(s) : Levomilnacipran
Therapeutic Area : Undisclosed
Highest Development Status : Phase IV
Sponsor : Allergan
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Forest Laboratories | Institute for Advanced Medical Research, Alpharetta, GA
Deal Size : Inapplicable
Deal Type : Inapplicable
Levomilnacipran ER vs. Adjunctive Quetiapine for Adults With Inadequate Relief With SSRIs in MDD
Details : Levomilnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 25, 2016
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Forest Laboratories | Institute for Advanced Medical Research, Alpharetta, GA
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Levomilnacipran ER in Adolescent Participants With Major Depressive Disorder
Details : Levomilnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 01, 2015
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Levomilnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase IV clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
November 11, 2014
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase IV
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Safety and Efficacy of Levomilnacipran ER (Levomilnacipran SR) in Major Depressive Disorder
Details : Levomilnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
June 21, 2011
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Levomilnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Depressive Disorder, Major.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
December 06, 2010
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase II
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Study Phase : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Levomilnacipran is a Other Small Molecule drug candidate, which is currently being evaluated in phase III clinical studies for the treatment of Depression.
Product Name : Undisclosed
Product Type : Miscellaneous
Upfront Cash : Inapplicable
March 12, 2010
Lead Product(s) : Levomilnacipran
Therapeutic Area : Psychiatry/Psychology
Highest Development Status : Phase III
Sponsor : Undisclosed
Deal Size : Inapplicable
Deal Type : Inapplicable
Reset All
